SUPN Strangle Strategy
SUPN (Supernus, Inc.), in the Healthcare sector, (Drug Manufacturers - Specialty & Generic industry), listed on NASDAQ.
Supernus, Inc. is a diversified biopharmaceutical company focused on developing and commercializing treatments for central nervous system (CNS) diseases. Its portfolio of 11 marketed products spans opioid use disorder, psychiatry, and neurology, and includes SUBLOCADE, a long-acting injectable buprenorphine for opioid use disorder, along with sublingual OUD treatments; Qelbree, a non-stimulant treatment for attention-deficit hyperactivity disorder (ADHD); GOCOVRI for dyskinesia in Parkinson’s disease patients receiving levodopa-based therapy; ONAPGO for motor fluctuations in advanced Parkinson’s disease; ZURZUVAE for postpartum depression; and treatments for epilepsy, migraine, cervical dystonia, and chronic sialorrhea, including Oxtellar XR, Trokendi XR, APOKYN, and MYOBLOC. The company also advances a pipeline of novel CNS product candidates. Its products are sold primarily in the United States, with additional markets including Canada, Australia, France, and Germany. The company was formed through the November 2026 merger of Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc., and is headquartered in Rockville, Maryland.
SUPN (Supernus, Inc.) trades in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a market capitalization of approximately $1.73B, a trailing P/E of 7.79, a beta of 0.52 versus the broader market, a 52-week range of 25.92-43.2, average daily share volume of 2.5M, a public-listing history dating back to 2012, approximately 827 full-time employees. These structural characteristics shape how SUPN stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.52 indicates SUPN has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure. The trailing P/E of 7.79 is on the value side, where IV often compresses outside event windows because forward growth expectations are already discounted into the share price. SUPN pays a dividend, which adjusts put-call parity and shifts the ex-dividend pricing across the listed chain.
What is a strangle on SUPN?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
SUPN snapshot
As of November 13, 2026, spot at $29.69, ATM IV 64.60%, IV rank 31.97%, expected move 18.52%. The strangle on SUPN below is built from the November 13, 2026 end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.
Why this strangle structure on SUPN specifically: SUPN IV at 64.60% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 18.52% (roughly $5.50 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated SUPN expiries trade a higher absolute premium for lower per-day decay. Position sizing on SUPN should anchor to the underlying notional of $29.69 per share and to the trader's directional view on SUPN stock.
SUPN strangle setup
The SUPN strangle below is built from the November 13, 2026 end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With SUPN at $29.69 on that close, the first option leg uses a $30.87 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed SUPN chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 SUPN shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $30.87 | $1.58 |
| Buy 1 | Put | $27.87 | $1.81 |
SUPN strangle risk and reward
- Net Premium / Debit
- -$338.50
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- -$338.50
- Breakeven(s)
- $24.49, $34.26
- Risk / Reward Ratio
- Unbounded
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
SUPN strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on SUPN. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | +$2,447.50 |
| $6.57 | -77.9% | +$1,791.15 |
| $13.14 | -55.8% | +$1,134.80 |
| $19.70 | -33.6% | +$478.44 |
| $26.26 | -11.5% | -$177.91 |
| $32.83 | +10.6% | -$142.74 |
| $39.39 | +32.7% | +$513.61 |
| $45.95 | +54.8% | +$1,169.96 |
| $52.52 | +76.9% | +$1,826.31 |
| $59.08 | +99.0% | +$2,482.67 |
When traders use strangle on SUPN
Strangles on SUPN are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the SUPN chain.
SUPN thesis for this strangle
The market-implied 1-standard-deviation range for SUPN extends from approximately $24.19 on the downside to $35.19 on the upside. A SUPN long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current SUPN IV rank near 31.97% is mid-range against its 1-year distribution, so the IV signal is neutral; the strangle thesis on SUPN should anchor more to the directional view and the expected-move geometry. As a Healthcare name, SUPN options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to SUPN-specific events.
SUPN strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. SUPN positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move SUPN alongside the broader basket even when SUPN-specific fundamentals are unchanged. Always rebuild the position from current SUPN chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on SUPN?
- A strangle on SUPN is the strangle strategy applied to SUPN (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With SUPN stock at $29.69 on the November 13, 2026 close, the strikes shown on this page are snapped to the nearest listed SUPN chain strike and the premiums come straight from that session's bid/ask midpoint.
- How are SUPN strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the SUPN strangle priced from the November 13, 2026 end-of-day chain at a 30-day expiry (ATM IV 64.60%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$338.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a SUPN strangle?
- The breakeven for the SUPN strangle priced on this page is roughly $24.49 and $34.26 at expiration, derived from the November 13, 2026 end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The SUPN market-implied 1-standard-deviation expected move in the same options snapshot is approximately 18.52%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on SUPN?
- Strangles on SUPN are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the SUPN chain.
- How does current SUPN implied volatility affect this strangle?
- SUPN ATM IV is at 64.60% with IV rank near 31.97%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.